Mayne Pharma Group (MYX.AX) Osake Kurssi
Mayne Pharma Group Kurssi
Liikevaihto on kasvanut 51,7 % vuodessa viimeisten 19 vuoden aikana 383,68 M AUD:een. Osakekohtainen tulos on laskenut 1,0 % vuodessa viimeisten 16 vuoden aikana. Mayne Pharma Groupn nettomarginaali on nyt 6,4 %, noussut −179,0 %:sta muutama vuosi sitten. Mayne Pharma Groupn osinkotuotto on tällä hetkellä noin 21,33 %. Jakosuhde on noin 38 % tuloksesta. Osinko on kasvanut 5,0 % vuodessa viimeisten 13 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 6,22 AUD, eli yli nykyhintaa 144,0 %. 5 analyytikosta 4 suosittaa ostoa — kokonaiskonsensus on Osta.
Mayne Pharma Group osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Mayne Pharma Group liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Mayne Pharma Group -osakkeesta
Mayne Pharma Group Ltd operates as a pharmaceutical company. Its business model revolves around developing, manufacturing, and distributing branded and generic prescription pharmaceuticals. Mayne Pharma specializes in providing contract development and manufacturing services to customers worldwide. By leveraging its expertise, capabilities, and global reach, Mayne Pharma aims to provide cost-effective and high-quality pharmaceutical products. The company focuses on various therapeutic areas, including cardiology, oncology, women's health, dermatology, and specialty products, catering to the needs of patients and healthcare professionals. Mayne Pharma Group Ltd strives to deliver innovative healthcare solutions and improve patient outcomes through its comprehensive business model.
Mayne Pharma Group Ltd is primarily active in the pharmaceutical industry.
The main competitors of Mayne Pharma Group Ltd in the market include companies like Teva Pharmaceutical Industries Ltd, Fagron NV, and Bio-Pharmaceutics, Inc. These companies operate in the pharmaceutical industry, focusing on generic drugs and specialty pharmaceuticals, similar to Mayne Pharma Group Ltd. By constantly monitoring and analyzing competition, Mayne Pharma Group Ltd strives to maintain its position and market share through strategic business decisions and product innovations.
Mayne Pharma Group Ltd is an Australian pharmaceutical company with a rich history and background. Founded in 1845 as FH Faulding & Co, it has established itself as a reputable player in the industry. In 2015, the company acquired the generic products division of a large U.S. pharmaceutical company, strengthening its global presence. Mayne Pharma Group Ltd specializes in the development and manufacture of generic and specialty pharmaceutical products, focusing on areas such as oncology, dermatology, and women's health. With a commitment to quality and innovation, Mayne Pharma Group Ltd continues to make significant contributions to the healthcare sector globally.
Mayne Pharma Group Ltd has achieved significant milestones in its journey. Some notable accomplishments include the acquisition of Metrics Contract Services, a contract development and manufacturing organization. This strategic move expanded the company's capability to offer a full-service platform for pharmaceutical development and manufacturing. Mayne Pharma also received FDA approval for various generic and specialty pharmaceutical products, further strengthening its market presence in the United States. Additionally, the company successfully launched new products, such as Doryx, in the dermatology segment, and secured international distribution agreements. Mayne Pharma Group Ltd continues to strive for innovative solutions in the pharmaceutical industry to enhance shareholder value and meet patient needs.
Mayne Pharma Group Ltd primarily operates in various countries and regions around the world. The company has a strong presence in Australia, where it is headquartered, and it also has a significant presence in the United States. With a focus on developing, manufacturing, and marketing branded and generic pharmaceutical products, Mayne Pharma Group Ltd serves customers and healthcare professionals in these key markets. Additionally, the company's global reach extends to other regions, including Europe and Asia, where it actively pursues business opportunities and fosters growth. Mayne Pharma Group Ltd's international presence underscores its commitment to delivering high-quality healthcare solutions to a diverse range of patients globally.
Mayne Pharma Group Ltd is a pharmaceutical company that values innovation, integrity, and patient care. With a commitment to developing high-quality, affordable medications, Mayne Pharma Group Ltd aims to improve the health and well-being of individuals worldwide. The company's corporate philosophy revolves around delivering effective solutions through research, development, and manufacturing of pharmaceutical products. Mayne Pharma Group Ltd prioritizes transparency, ethical practices, and collaboration in its operations, ensuring compliance with regulatory standards. By focusing on customer needs and advancing pharmaceutical technologies, Mayne Pharma Group Ltd continues to build a reputation as a trusted and forward-thinking healthcare organization.
Analyytikot asettavat tällä hetkellä Mayne Pharma Group-osakkeelle keskimääräisen tavoitehinnan 6,22 AUD (mediaani: 6,22 AUD), mikä merkitsee +144,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 5 analyytikkoarvioon.
5 analyytikkoa arvioi tällä hetkellä Mayne Pharma Group-osaketta: 4 suosittaa ostoa, 1 pitoa ja 0 myyntiä.
Nykyisellä valuuttakurssilla Mayne Pharma Group-osake noteerataan hintaan 1,59 EUR (2,55 AUD).
Mayne Pharma Group-osake (MYX.AX) on listattuna 5 pörssissä, muun muassa: ASX (MYX.AX), Frankfurt (HG6.F), Düsseldorf (HG6.DU), Hamburg (HG6.HM).
Mayne Pharma Group Ltd is an Australian pharmaceutical company headquartered in Salisbury, South Australia. It was founded in 2015 through the merger of Mayne Pharma Limited and Hospira Australia Pty Ltd. The company specializes in the development, manufacturing, and marketing of generic and specialized pharmaceutical products. Overall, the company operates in four main business segments: generics, specialized products, contract manufacturing, and distribution in the United States. Mayne Pharma's generics division produces a wide range of pharmaceutical products in various categories such as cardiology, gastroenterology, analgesics, and antibiotics. Mayne Pharma is also involved in the manufacture of generics with controlled release of active ingredients and long-acting generics. Mayne Pharma's specialized products are medicines used to treat rare or chronic diseases and often have higher added value than standard generics. This includes products in the fields of dermatology, oncology, endocrinology, urology, and psychiatry. Mayne Pharma also operates contract manufacturing, using its own infrastructure to manufacture products on behalf of third parties. Mayne Pharma's contract manufacturing offers both small and large molecule products. This option allows companies to manufacture their own products without having to build their own production and development system. In the United States, Mayne Pharma is involved in the distribution of pharmaceutical products and operates a distribution channel in the industry. This expands Mayne Pharma's portfolio with commercially attractive and acquired active ingredients and excipients. Mayne Pharma has a strong portfolio of products and assets to make it a leading provider of generic and specialized pharmaceuticals. The company also has a solid pipeline of compounds in various stages to support future growth. Mayne Pharma's success is based on a combination of high quality standards, competitive prices, a strong pipeline portfolio, and a dedicated strategic partnership with other companies in the industry. Mayne Pharma is focused on providing its customers with high quality and affordable medications and strengthening its leadership position in global markets.
liikevaihto Mayne Pharma Group on 383,68 M AUD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
voitto Mayne Pharma Group on 24,47 M AUD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Mayne Pharma Group:n hinta-voitto-suhde (P/E) on tällä hetkellä 9,85. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Mayne Pharma Group-osakkeen arvostusta.
Mayne Pharma Group:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,63. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Mayne Pharma Group-osakkeen arvostuskennuslukuna.
Mayne Pharma Group:n Eulpool-laatuscore on 3/10.
Mayne Pharma Group:n ISIN on AU000000MYX0. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Mayne Pharma Group:n WKN on A1C821. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Mayne Pharma Group:n ticker on MYX.AX. Tämä pörssinoteeraus käytetään Mayne Pharma Group-osakkeiden kauppaan pörssissä.
Mayne Pharma Group osake
Mayne Pharma Group vertaisryhmä
Mayne Pharma Group Ticker
Mayne Pharma Group FIGI
Kaikki tunnusluvut ja syvällinen analyysi Mayne Pharma Group:sta
Meidän osakeanalyysimme Mayne Pharma Group-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Mayne Pharma Group:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: